'Columvi,' a first-in-class bispecific antibody for lymphoma treatment, will make another attempt to be considered for reimbursement listing.

According to industry sources, Roche Korea has recently submitted a reimbursement application for the CD20·CD3 bispecific antibody Diffuse Large B-Cell Lymphoma (DLBCL) treatment Columvi (glofitamab).

The drug was initially considered for the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HIRA) in July but failed to set reimbursement criteria. Whether Columvi will successfully win reimbursement listing gathers attention.

Columvi was approved in December last year as a treatment for patients wi